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HOSPITAL-ACQUIRED, LABORATORY-CONFIRMED
BLOODSTREAM INFECTION: INCREASED HOSPITAL STAY
AND DIRECT COSTS
Giovanni Battista Orsi, MD; Lidia Di Stefano, MD; Norman Noah, MB, FRCP
OBJECTIVES: To determine increased hospital stay and
direct costs attributable to hospital-acquired, laboratory-confirmed
bloodstream infection (BSI), and to evaluate the matching variable
length of stay (LOS).
DESIGN: Retrospective (historical) cohort study with 1:2
matching in intensive care units and surgical wards.
SETTING: A 2,000-bed university hospital in Rome, Italy.
PATIENTS: All patients admitted between January 1994
and June 1995 who had hospital-acquired, laboratory-confirmed
BSI were considered cases; all others were eligible as controls.
METHODS: Two controls (A and B) were selected per
case in a stepwise fashion. Controls in group A were selected
according to the following six criteria: ward, gender, age, diagno-
sis, central venous catheter, and LOS equal to the interval from
admission to infection in a matched case ± 20% (LOS ± 20%).
Controls in group B were selected according to the first five crite-
ria, but excluded LOS ± 20%.
RESULTS: One hundred five of 108 patients were each
matched with two controls. The matching appropriateness score
was greater than 90%. With the use of controls in groups A and B,
the case-fatality rates attributable to hospital-acquired, laboratory-
confirmed BSI were 35.2% and 40.9%, respectively; the estimated
risk ratios for death were 2.60 and 3.52 (P = .0001), respectively.
The increased hospital stay per case attributable to hospital-
acquired, laboratory-confirmed BSI was 19.1 (mean) and 13.0
(median) days for matched pairs in control group A and 19.9
(mean) and 15.0 (median) days for matched pairs in control group
B. With controls in group A, the cost of increased hospital stay per
patient attributable to hospital-acquired, laboratory-confirmed BSI
was Euro 15,413. The additional cost per patient due to treatment 
was Euro 943, making the overall direct cost Euro 16,356 per case.
CONCLUSIONS: This study should make it possible to
estimate the cost of hospital-acquired, laboratory-confirmed BSI in
most hospitals after adjusting for incidence rate. It also confirmed
the use of LOS ± 20% as a matching variable to limit overestimation
of increased hospital stay. To our knowledge, this is among the
first such studies in Europe (Infect Control Hosp Epidemiol
2002;23:190-197).
Hospital-acquired, laboratory-confirmed blood-
stream infection (BSI) is an important cause of morbidity
and mortality, adding significantly to the economic burden
of hospitals.1-5 There are costs with all hospital infections.
The direct costs are represented principally by increased
hospital stay, drug treatment, and medical and surgical pro-
cedures. Indirect costs include the patient’s lost salary, rel-
atives’ time, and infirmity. Because it is difficult to evaluate
all variables exactly, especially indirect costs, investigators
generally estimate only direct additional costs and, particu-
larly, additional days of stay, which represent the single
most expensive element.1,6
Studies performed to estimate increased hospital
stay and related costs attributable to hospital-acquired, lab-
oratory-confirmed BSI report results ranging from 7 to 30
days,2,7-13 depending principally on microorganisms9,13 and
type of ward (eg, intensive care unit [ICU]).7,10,11 The relat-
ed costs range from $3,061 to $40,000.2 Most of these were
case–control studies.
Although case–control studies need careful selection of
the matching parameters and are considered to overestimate
the attributable days and costs, they are the most expedient
and the most often used studies.4,6,7,10,13-16 To improve match-
ing, some investigators introduced a scoring system that mea-
sures precisely the matching appropriateness of controls and,
to avoid overestimating the length of hospitalization, an impor-
tant matching criterion that stipulates the “length of stay in
controls equal to the interval from admission to infection in
cases ± 10%” (LOS ± 10%).10 Although the scoring system is
undoubtedly useful, the LOS ± 10% criterion might itself be a
confounding factor because it directly affects the LOS in con-
trols and could lead to overmatching.
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Therefore, we decided to perform a controlled study
to estimate the increased hospital stay attributable to hos-
pital-acquired, laboratory-confirmed BSI and its economic
burden in a large teaching hospital in Rome, Italy. Further-
more, we evaluated the eventual influence of the LOS
matching criterion in estimating the increased hospital stay
caused by hospital-acquired, laboratory-confirmed BSI in
surgical and ICU patients. We used ± 20% rather than ± 10%
to match more easily. To our knowledge, this is one of the
first such studies in Europe.
METHODS
The study was conducted in the 2,000-bed university
hospital “Policlinico Umberto I” of Rome. It covered 8 wards
(total, 167 beds): 3 general surgery (66 beds), 1 thoracic
surgery (20 beds), 1 vascular surgery (18 beds), 1 neuro-
traumatology (10 beds), 1 ICU (14 beds), and 1 cardiovascu-
lar surgery (39 beds). These wards were considered to be
representative of surgical and intensive care adult wards.
Definitions
We followed international consensus definitions for
laboratory-confirmed BSI17-20 as the isolation of 1 or more
microorganisms from the blood culture of a patient with 2
or more of the following: temperature greater than 38°C or
less than 36°C; heart rate greater than 90 beats per minute;
respiratory rate greater than 20 breaths per minute; and
white blood cell count greater than 12,000/mm3, less than
4,000/mm3, or greater than 10% immature neutrophils.
Catheter-related, laboratory-confirmed BSI was defined as
above plus the isolation of the same microorganism from a
semiquantitative culture from a central venous catheter and
a peripheral blood sample.21 Any patient who had laborato-
ry-confirmed BSI 48 hours or more after admission to the
ward was included. Primary BSI referred to that for which
there was no other documented site of infection other than
catheter-related BSI. Secondary BSI was defined as BSI
subsequent to a documented infection with the same
microorganism present at another site of the body.19
Data Collection
Data from clinical and microbiological records were
collected by an infection control team, using a specially
designed form. Any information necessary to evaluate mor-
bidity, mortality, increased hospital stay, and economic bur-
den of hospital-acquired, laboratory-confirmed BSI was
recorded. The surveillance form included general ques-
tions about the patient, factors relevant for the diagnosis of
hospital-acquired, laboratory-confirmed BSI, and data
about microorganisms isolated, their antibiograms, and
general therapy.
All of the data were coded and entered into a com-
puter for statistical analysis using Stata-Data software
(Apple Computer, Inc., Cupertino, CA).
Matching
We performed a retrospective (historical) cohort
study with 1:2 matching in which all patients who were
admitted to the selected wards between January 1994 and
June 1995 and who had hospital-acquired, laboratory-con-
firmed BSI were considered cases. All other patients who
had no evidence of hospital-acquired, laboratory-confirmed
BSI at any time during their hospitalization were eligible as
controls. When cases had more than one episode of hospi-
tal-acquired, laboratory-confirmed BSI infection, only the
first episode was considered.10,13
On the basis of a preceding study,10 we selected con-
trols (group A) in a stepwise fashion, according to 6 match-
ing variables with a 25-point scoring system, including LOS
equal to the interval from admission to infection in cases ±
20% (LOS ± 20%) (5 points); primary diagnosis (based on the
International Classification of Diseases) (5 points); same
ward of admission (5 points); presence of a central venous
catheter (4 points); age ± 5 years (4 points); and same gen-
der (2 points). Also, to evaluate the influence of a single
matching criterion (LOS ± 20%) on the estimate of increased
hospital stay, we selected a second set of controls (group B)
using all of the above variables except LOS ± 20% (20-point
matching appropriateness score).
Estimation of Increased Hospital Stay
Increased hospital stay was the difference in the LOS
between each case and control pair (A and B) during the
period in the ward cluster. No patient who had hospital-
acquired, laboratory-confirmed BSI was transferred to
another ward before recovering from the infection. Hence,
to estimate the increased hospital stay, we did not consider
the overall hospital stay of patients, but only the period
spent in the ward. The increased hospital stay ratio, as
defined by us, was the increased hospital stay of cases to
controls.
In estimating the increased hospital stay, we consid-
ered (in order):
1. Control groups A and B, all matched pairs;
2. Control groups A and B, fully matched pairs only;
3. Control group A, fully matched pairs for LOS ± 20%
criterion;
4. Control groups A and B, shared matched pairs;
5. Control groups A and B, survived matched pairs; and
6. Control group A, 3 subgroups (pairs matched on LOS
less than 10%, LOS 10% to 20%, and LOS greater than 20%).
Costs
Direct increased hospital costs were estimated using
only controls in group A and depended on increased LOS
and treatment. We chose control group A because most
studies10-13 have estimated costs using the LOS ± 20% crite-
rion. The cost of LOS was evaluated by multiplying the
increased hospital stay by the daily hospital cost. The hos-
pital management estimated the “hotel” average daily cost
as Euro 400 in the surgical ward and Euro 1,200 in the ICU;
this also included medical and nursing time. Treatment
was evaluated on the basis of antibiotic therapy related to
hospital-acquired, laboratory-confirmed BSI. We reviewed
the chart of each individual to evaluate antibiotic dosage
exactly. The antibiotic cost per unit was based on the prices
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actually paid by the hospital, which were 50% of the indus-
try prices.
The LOS and overall costs were further compared in
conditions in which both cases and controls survived (sur-
vivor-matched pairs). The comparisons were made sepa-
rately because mortality was expected to affect the LOS
and costs.
RESULTS
A total of 5,106 clinical records were screened: 677 in
the ICU: 453 in neurotraumatology; 698 in general surgery
I; 778 in general surgery II; 557 in thoracic surgery; 258 in
vascular surgery; 1,317 in cardiosurgery; and 368 in gener-
al surgery III. The ages of the study population ranged
from 0 to 93 years, with a mean of 53.7 years (standard devi-
ation [SD], 17.5 years). Males outnumbered females by 2 to
1. Hospital-acquired, laboratory-confirmed BSI was diag-
nosed in 108 (2%) patients. Three cases were excluded
from the matching because of missing data, leaving 105
cases successfully matched. The ages ranged from 17 to 82
years, with a mean of 53.6 years (SD, 17.4 years). Seventy-
five were men (71.4%) and 30 were women (28.6%). The
number of cases and relative incidence varied significantly
(P = .0001) between the wards: 65 in the ICU (9.6%); 15 in
neurotraumatology (3.3%); 16 in general surgery II (2.0%);
7 in the cardiosurgery unit (0.5%); and 1 each in general
surgery III (0.3%) and thoracic surgery (0.2%). None were
found in general surgery I or vascular surgery.
Of the 105 cases, 83 (79.5%) were primary laborato-
ry-confirmed BSI, including 19 (18.1%) catheter-related,
laboratory-confirmed BSI, and 22 (20.0%) were secondary
laboratory-confirmed BSI.
Microorganisms
Among the 105 matched patients, the most common
microorganisms isolated were coagulase-negative staphylo-
cocci (33.0%) and Staphylococcus aureus (19.7%), followed
by Pseudomonas aeruginosa (11.2%), Acinetobacter (8.0%),
enterococci (5.3%), Candida albicans (3.7%), Enterobacter
(3.7%), and others (15.4%).
Mortality
The crude case-fatality rate was 57.1% in cases. It was
21.9% in controls in group A and 16.2% in controls in group
B. Therefore, the case-fatality rates attributable to hospital-
acquired, laboratory-confirmed BSI were 35.2% and 40.9%
and the estimated risk ratios for death were 2.60 and 3.52
(P = .0001), respectively. Risk of death among cases was
higher in the ICU (67.7%) than in surgical wards (41.5%) (P
= .0054). The ages of the patients who died ranged from 17
to 82 years (mean, 59.9 years; SD, 15.1 years). The risk of
death increased with age in our series, as in others.22-24
TABLE 1
CASE–CONTROL MATCHING APPROPRIATENESS SCORE WITH GROUPS A AND B
Pairs of Matching 
Patients % Score Points Appropriateness (%)
Group A 60 57.1 25 1,500 100
1 1.0 23 23 92
8 7.6 21 168 84
27 25.7 20 540 80
2 1.9 19 38 76
2 1.9 16 32 64
3 2.8 15 45 60
1 1.0 14 14 56
1 1.0 11 11 44
Total 105 100 2,371
Average 22.6
Overall 90.3
Group B 89 84.8 20.0 1,780 100
1 1.0 18.0 18 90
7 6.7 16.0 112 80
2 1.9 15 30 75
1 1.0 14 14 70
1 1.0 12 12 60
1 1.0 11 11 55
3 2.8 9 18 45
Total 105 100 1,995
Average 19.0
Overall 95.0
This content downloaded from 194.80.229.244 on Wed, 9 Oct 2013 13:09:25 PM
All use subject to JSTOR Terms and Conditions
Vol. 23, No. 4 HOSPITAL-ACQUIRED, LABORATORY-CONFIRMED BSI 193
Matching Appropriateness
The use of the scoring system made it possible to
evaluate the appropriateness of matching. With matching
in group A, the average score for controls was 22.6 (90.3%
matching appropriateness) (Table 1). In 96 of 105 controls
(> 90.0%), the scores were 20 or more (80% matching appro-
priateness). With matching in group B, the average score
for controls was 19.0 (95.0% matching appropriateness)
(Table 1). In 97 of 105 controls (> 90.0%), the scores were
16 (80% matching appropriateness). In 39 matches, the
scores for controls in groups A and B were the same
(37.1%).
Sixty (57.1%) controls in group A and 89 (84.8%) con-
trols in group B were fully matched with cases on all crite-
ria (Table 1). The ward of admission criterion was satisfied
by all controls in both groups A and B. All except 1 (99.5%)
control in group A and 3 (97.1%) controls in group B met
the age criterion. All but 4 (96.2%) controls in group A and
5 (95.2%) controls in group B were matched for gender.
Ninety-seven (92.4%) controls in group A and 99 (94.3%)
controls in group B matched cases for diagnosis on admis-
sion. Ninety-two (87.6%) controls in group A and 94 (89.5%)
controls in group B were matched for presence of a central
venous catheter. Seventy-five (71.4%) controls in group A
satisfied the criterion for LOS.
Hospital LOS
Hospital stay in cases ranged from 3 to 163 days (1 to
73 days in control group A and 1 to 42 days in control group
B). Increased hospital stay attributable to hospital-
acquired, laboratory-confirmed BSI was 2,004 days (mean,
19.1 days; median, 13.0 days) in the A-matched pairs and
2,091 days (mean, 19.9 days; median, 15.0 days) in the B-
matched pairs (Table 2). When groups A and B were con-
sidered separately, the increased hospital stay was 15.7 and
18.7 days in the ICU and 24.6 and 21.9 days in surgical
wards, respectively. The increased hospital stay ratios were
2.83 and 3.10, respectively (Table 2).
In control group A, the mean LOS up to the time of
laboratory-confirmed BSI was 12.0 ± 14.2 days in cases and
10.4 ± 9.5 days in matched controls. We also evaluated the
increased hospital stay in control group A (60 pairs) and
control group B (89 pairs), using only those who were fully
matched (Table 3). Furthermore, among controls in group
A, we evaluated only the 75 pairs (71%) fully matched for
the LOS criterion. The mean increased LOS in this group
was 16.0 days (Table 3). 
When only the 39 patients (37.1%) shared by the two
control groups were considered, the increased hospital
stay attributable to hospital-acquired, laboratory-confirmed
BSI was 928 days (mean, 23.8 days; median, 17.0 days)
(Table 3). Matching separately by groups A and B, we
selected 36 survived pairs. The overall increased LOS
attributable to hospital-acquired, laboratory-confirmed BSI
was 741 days (mean, 20.6 days; median, 20.0 days) in group
A and 730 days (mean, 20.3 days; median, 17.5 days) in
group B (Table 4). When groups A and B were considered
separately, the increased hospital stay was 16.1 and 15.1
days in the ICU and 23.8 and 24.0 days in the surgical
wards, respectively (Table 4).
Furthermore, among the 105 controls in group A, we
selected 3 subgroups (LOS less than 10%, LOS 10% to 20%,
and LOS greater than 20%) according to the matching cri-
terion LOS ± 20%. The results showed that the mean
increased hospital stay was 14.6 days in the LOS less than
10% subgroup, 16.9 days in the LOS 10% to 20% subgroup,
TABLE 2
INCREASED HOSPITAL STAY ATTRIBUTABLE TO HOSPITAL-ACQUIRED, LABORATORY-CONFIRMED BLOODSTREAM INFECTION FOR CONTROL
GROUPS A AND B
Control Control
Group A Group B Control Control
Control Control Increased Increased Group A Group B
Hospital- Group A Group B Hospital Hospital Increased Increased
No. of Days for Hospital- Hospital- Stay Stay Hospital Hospital
Ward Cases Cases Days Days Per Case* Per Case* Stay Ratio Stay Ratio
ICU 65 1,550 529 336 15.7 18.7 2.94 4.57
All surgeries 40 1,549 566 672 24.6 21.9 2.73 2.30
NT 15 640 167 212 31.5 28.5 3.83 3.18
GS II 16 511 195 271 19.7 15.0 2.61 1.88
GS III 1 53 38 10 15.0 43.0 1.39 5.30
Thoracic 1 14 4 4 10.0 10.0 3.50 3.50
Cardiosurgery 7 331 162 175 24.1 22.3 2.04 1.89
Total 105 3,099 1,095 1,008
Mean 19.1 19.9 2.83 3.10
Median 13.0 15.0 2.44 3.53
NT = neurotraumatology; GS II = general surgery II; GS III = general surgery III.
*Mean days.
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and 26.9 days in the LOS greater than 20% subgroup (Table
3).
Costs
With application of the single-day hospital cost to
the increased hospital stay attributable to hospital-
acquired, laboratory-confirmed BSI (only for control
group A), the overall additional expenditure was Euro
15,413 per case (Table 5). ICU costs per case were almost
double those for surgical wards and, overall, represented
three-quarters of the total cost of Euro 1,225,200. For the
36 matched pairs who survived, the total cost was Euro
490,000, representing Euro 13,611 per case.
With the use of control group B, the above costs
increased proportionally to the incremental increased hos-
pital stay. The antibiotic costs related to hospital-acquired,
laboratory-confirmed BSI accounted for 5.6% of the total
hospital-acquired, laboratory-confirmed BSI cost (Table
5).
DISCUSSION
Of the various methods used to estimate the
increased hospital stay caused by hospital-acquired, labo-
ratory-confirmed BSI, the matched case–control method
used here is the most appropriate and the most tested.
However, because it assumes that any difference in LOS is
attributable to infection and not related to other inherent
differences between the patient groups, it is generally con-
sidered to overestimate slightly the attributable days and
costs.4,6,7,10,11,13,15,16
Even with close matching (1:1), case–control studies
may have serious biases.14 One is the difficulty of selecting
TABLE 3
INCREASED HOSPITAL STAY ATTRIBUTABLE TO HOSPITAL-ACQUIRED, LABORATORY-CONFIRMED BLOODSTREAM INFECTION USING DIFFERENT
MATCHING METHODS
Control Group A Control Group B
No. of Matched Pairs Increased Stay* No. of Matched Pairs Increased Stay*
All pairs 105 19.1 105 19.9
Fully matched 60 16.9 89 22.0
Pairs shared by the two control groups 39 23.8 39 23.8
Survived pairs 36 20.6 36 20.3
Fully matched for LOS ± 20% 75 16.0
Matched with control LOS < 10% 34 14.6
Matched with control LOS 10% to 20% 41 16.9
Matched with control LOS > 20% 30 26.9
LOS = length of stay.
*Mean days.
TABLE 4
INCREASED HOSPITAL STAY ATTRIBUTABLE TO HOSPITAL-ACQUIRED, LABORATORY-CONFIRMED BLOODSTREAM INFECTION IN THE SURVIVED
MATCHED PAIRS FROM CONTROL GROUPS A AND B
Control Control
Group A Group B Control Control
Increased Increased Group A Group B
Hospital Hospital Increased Increased
No. of Stay Stay Hospital Hospital
Ward Cases and Controls Per Case* Per Case* Stay Ratio Stay Ratio
ICU 15 16.1 15.1 2.82 2.79
All surgeries 21 23.8 24.0 2.37 2.41
NT 5 26.6 25.4 2.92 2.69
GS II 12 22.1 18.3 2.64 1.93
GS III 1 15.0 4.3 1.39 5.3
Cardiosurgery 3 28.6 38.0 4.40 2.7
Total 36 20.6 20.3 2.50 2.50
Median 20.0 17.5 2.90 2.45
Geometric mean 17.0 17.7 2.63 2.98
NT = neurotraumatology; GS II = general surgery II; GS III = general surgery III.
*Mean days.
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and measuring all appropriate matching variables to elimi-
nate all confounding factors and obtain suitable controls
from the uninfected patient pool. To minimize this, we
adopted a scoring system that allowed us to evaluate pre-
cisely the matching appropriateness of controls.10 The final
high matching score with both control groups (> 90%) in
105 cases was encouraging. Other studies with similar
matching appropriateness responses have generally been
conducted with smaller numbers of patients.10,11
Unfortunately, because this was a retrospective epi-
demiologic study, specific severity of illness scores (ie,
APACHE, SAPS I, and SAPS II) were not available for all
patients.11 Therefore, because the presence of a central
venous catheter may be an indirect sign of the severity of a
patient’s illness, it was adopted as a matching criterion.
Another potential bias was the exclusion of patients
for whom suitable controls could not be found. It has been
reported that these patients differ in terms of severity of ill-
ness.14 In our study, only 3 of 108 cases were unmatched.
This was because important variables were missing, not
because of a lack of controls.
Our case definitions fulfilled international guidelines,
facilitating comparison of our results with those of other
studies.17,18,21 The aim of our study was to estimate the over-
all increased hospital stay and costs attributable to hospital-
acquired, laboratory-confirmed BSIs. Consequently, in the
results, we did not distinguish whether these were catheter
related. The 22 cases of catheter-related BSI did not pre-
sent with any microbiological or clinical sign that could be
related to another site of infection. However, because this
study was retrospective, in a few cases a second site of
infection in the presence of a catheter-related BSI might
have been misdiagnosed by the clinicians on the ward.
The age and gender distribution of the cases was
similar to that of the overall study population. The overall
incidence and pathogen-specific rates of hospital-acquired,
laboratory-confirmed BSI were similar to those observed
in large teaching hospitals elsewhere.21,24-26 The method
used to select patients for the study was designed not to
estimate the incidence of hospital-acquired, laboratory-con-
firmed BSI, but rather to obtain a representative sample of
adult cases of hospital-acquired, laboratory-confirmed BSI
in a busy teaching hospital. It is possible that some cases
were undiagnosed or were treated or died before diagno-
sis.
The risk of death increased with age.22-24,26 Contrary
to other reports,22,24-26 in our study females (average age,
53.0 years) had a higher death rate (70.0%) than did males
(average age, 55.2 years) (52.0%).
Because no patient who had hospital-acquired, labo-
ratory-confirmed BSI was transferred to another ward
before recovering from infection, using the ward hospital
stay in cases was justified. Otherwise, it might have attrib-
uted additional days not related to the BSI. Also, consider-
ing only the time in the ward probably limited the overesti-
mation of the case–control method.6,14-16
In another study, Pittet et al.10 found a median
increased hospital stay of 14 and 24 days for all pairs and
survived pairs, respectively. Other studies reported esti-
mated increased hospital stays ranging from 8.5 to 39
days.8,9,11-13
Surprisingly, our results showed only a small differ-
ence in the increased hospital stay attributable to hospital-
acquired, laboratory-confirmed BSI between control
groups A (mean, 19.1 days; median, 13.0 days) and B
(mean, 19.9 days; median, 15.0 days). The hospital stay
among controls in group A (1,095 days) was only 8.6%
longer than that among controls in group B (1,008 days).
The increased hospital stay ratio was 9.5%. However, the
overall incremental stay estimate reported in our study
(using both groups A and B) is within the wide range found
in the literature.8,9,10-13
Conclusions from case–control studies are often
limited by obtaining suitable matches for available infect-
ed patients from the uninfected pool.4,6,7,10,11,13,15,16
Therefore, we also examined the increased hospital stay
using different matching methods. The average overall
hospital stay in controls (10.4) was only 1.6 days shorter
TABLE 5
ADDITIONAL DIRECT COSTS ATTRIBUTABLE TO HOSPITAL-ACQUIRED, LABORATORY-CONFIRMED BLOODSTREAM INFECTION
Additional Additional Antibiotic Total
No. of Days Days Cost Antibiotic Cost Total Cost
Ward Cases Cost (Euro) (Euro) per Case Cost (Euro) (Euro) per Case Cost (Euro) (Euro) per Case
ICU 65 1,225,200 18,849 50,118 771 1,275,318 19,620
All surgeries 40 393,200 9,830 48,956 1,224 442,156 11,054
NT 15 189,200 12,600 27,700 1,847 216,900 14,460
GS II 16 126,400 7,900 11,040 690 137,440 8,590
GS III 1 6,000 6,000 668 668 6,668 6,668
Thoracic 1 4,000 4,000 725 725 4,725 4,725
Cardiosurgery 7 67,600 9,657 8,823 1,260 76,423 10,917
Total 105 1,618,400 15,413 99,074 943 1,717,474 16,356
NT = neurotraumatology; GS II = general surgery II; GS III = general surgery III.
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than the hospital stay from admission to infection in cases
(12.0). Thus, the average overall difference between the
two cohorts (cases vs controls) was within the LOS ± 20%
matching criterion.
Because, in common with other similar studies,10-13 it
was not possible to fully match controls for all cases, leav-
ing concern as to how this could have affected the final
results, we estimated the increased hospital stay (mean)
considering only the fully matched pairs in control groups
A and B. The difference in LOS between fully matched
pairs and all pairs was 2.2 days in control group A and 2.1
days in control group B. When the difficulty in obtaining a
sufficient number of suitable controls in such studies and
the small difference in the results using only the fully
matched pairs are considered, the credibility of our study is
strengthened.
Moreover, because not all cases in control group A
were fully matched for LOS, which is considered the most
important criterion, we considered separately the 71% (75
pairs) who were fully matched for the LOS ± 20% criterion.
The hospital stay was 1,972 days (mean, 26.3 days; median,
21 days) for these cases and 776 days (mean, 10.3 days;
median, 8 days) for controls. Therefore, in this LOS-
matched subgroup, the final increased hospital stay was
16.0 days (mean) compared with 19.1 days using all con-
trols in group A.
Matching both groups A and B, we found a longer
increased LOS in the surgical wards (24.6 and 21.9 days,
respectively) than in the ICU (15.7 and 18.7 days, respec-
tively). In our opinion, there are several explanations for
this. First, the shorter hospitalization in the ICU was prob-
ably influenced by the much higher crude mortality rate for
these patients (67.7%) compared with surgical patients
(40.0%) (P = .0054). Second, as reported below, patients
from the ICU who survived were transferred to other
wards in the hospital. Third, neurotraumatology and gen-
eral surgery II, which had a transplant unit, could be con-
sidered an intensive care area, with patients in critical con-
dition.
It was also surprising that the 36 survived matched
pairs (with groups A and B) showed an increased LOS
ranging from only 20.3 to 20.6 days (mean).10,13 This could
be because, of 15 ICU survived matched cases, 11 patients
were transferred to other wards in the hospital once their
conditions improved. If the days of hospitalization outside
of the ICU were also considered, the overall increased LOS
would have been 25.2 and 25.5 days (mean).
Because using LOS ± 20%, rather than LOS ± 10%,10
allowed us to match controls more easily, we evaluated the
possible influence of this single variable. Results showed
that the subgroup LOS 10% to 20% compared with LOS less
than 10% accounted for only a 15.7% incremental stay,
whereas the 30 controls with LOS greater than 20% pre-
sented a much larger increase in LOS (84.2%). The LOS
reported in the three control subgroups was close (9.29,
11.4, and 10.6) to the median interval between hospital
admission and detection of hospital-acquired, laboratory-
confirmed BSI in cases (9.0 days).
Our study showed that the variable LOS ± 20%
reduced the estimated increased LOS only by less than
10%. Because case–control studies are considered to over-
estimate the increased LOS, we think that this variable
should be used in future studies. Because of the size of the
patient pool from which matched controls are drawn, as
more matching variables are used, fewer patients with hos-
pital-acquired, laboratory-confirmed BSI will be included in
the study. Therefore, the above criterion could be excluded
when the number of uninfected patients is small and there
is a need not to lose cases, with the possibility of adjusting
the final extra cost by reducing it by approximately 10%. 
Our estimate of the final cost per patient attributable
to increased LOS was Euro 15,413. However, because we
considered only the hospital stays within the study wards,
and some of the surviving ICU patients were transferred to
other wards, this final estimate is, if anything, a conserva-
tive one. The cost per patient attributable to increased LOS
among the 36 survived matched pairs of Euro 13,611 was
lower than the overall amount of Euro 15,413. This is prob-
ably because, among survivors, there were fewer patients
in the ICU (41.7% vs 61.3%). The costs per case due to
increased LOS were twice as high in the ICU compared
with all other surgical units (Euro 18,849 vs 9,830). The
cost of antibiotic treatment related to hospital-acquired, lab-
oratory-confirmed BSI varied from Euro 1,847 per case in
neurotraumatology to Euro 690 per case in general surgery
II. This was influenced by the different increased LOS
between wards and the wide range of antibiotics pre-
scribed. When only the 36 survived matched pairs are con-
sidered, the cost for cases was Euro 27,649, representing
Euro 768 per patient. This is explained by the fact that the
patients who recovered were treated for a shorter period
(10.4 days) compared with the total (12.7 days).
Finally, the overall direct cost attributable to hospital-
acquired, laboratory-confirmed BSI was Euro 16,356 per
case. Because more than one-third of hospital-acquired,
laboratory-confirmed BSI is considered preventable,27 the
overall expenditure attributable to hospital-acquired, labo-
ratory-confirmed BSI (Euro 1,717,474) could have been
reduced considerably. Our study shows the possible bene-
fits, in terms of health and cost savings, when hospital-
acquired, laboratory-confirmed BSI is prevented. From our
study, it should be possible to estimate the burden of labo-
ratory-confirmed bloodstream infection after adjusting for
hospital incidence rates.
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